Cost Analysis of XELOX and FOLFOX-4 Chemotherapy Regimens for Colorectal Carcinoma

Česká verzia

Authors: T. Büchler ¹; A. Nohejlová Medková ¹; M. Kupec ¹; M. Bláha ²; T. Pavlík ²; L. Dušek ²; J. Abrahámová ¹
Authors place of work: Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha ¹; Institut biostatistiky a analýz, Masarykova univerzita, Brno ²
Published in the journal: Klin Onkol 2012; 25(6): 440-444
Category: Original Articles

Práce byla podpořena grantem Operačního programu Vzdělávání pro konkurenceschopnost MZ ČR, EU a Evropského sociálního fondu v ČR: Edukační a informační platforma onkologických center pro podporu a modernizaci vzdělávání a lékařských a příbuzných medicínských oborech. CZ 2.07/2.4.00/31.0020.

TB a ANM dostali honoráře za přednášky od společností Roche a Medonet. Ostatní autoři prohlašují, že nemají konflikt zájmů.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do bi omedicínských časopisů.

Summary

Background:
The aim of our study was to compare healthcare-related costs of treatment with XELOX and FOLFOX4 chemotherapeutic regimens in patients with colorectal cancer. We have evaluated costs claimed to the health insurance by the hospital administering these cancer therapies. This study is a pilot project utilising the new I-COP database developed by the Institute of Biostatistics and Analyses of the Masaryk University in Brno, Czech Republic.

Patients and Methods:
First, we estimated the costs based on current prices of procedures, medication, and materials from public sources. Using the I-COP database, we then carried out a matched-pair comparison of 26 patients treated with FOLFOX4 or XELOX for colorectal cancer. We evaluated a period of three months of therapy (i.e. 6 cycles of FOLFOX4 or 4 cycles of XELOX). Statistical analysis was done using the Wilcoxon matched pairs test.

Results:
The estimated cost for three months of therapy was 148,288 Czech crowns (CZK) for FOLFOX4 (including CZK 101,064 for chemotherapy drugs) and CZK 123,756 for XELOX. The overall costs claimed to the insurance companies were CZK 160,158 and CZK 151,176 for FOLFOX4 and XELOX, respectively (p = 0.221). The XELOX regimen had significantly higher costs for chemotherapy drugs (CZK 131,705 versus 114,531, p = 0.023) whereas other costs were lower than those for FOLFOX4.

Conclusions:
FOLFOX4 and XELOX regimens can be considered as equivalent in terms of costs claimed by the hospital administering cancer treatment.

Key words:
costs – cost analysis – chemotherapy – colorectal cancer

Zdroje

1. Silvestris N, Maiello E, De Vita F et al. Update on capecitabine alone and in combination regimens in colorectal cancer patients. Cancer Treat Rev 2010; 36 (Suppl 3): S46–S55.

2. Fínek J, Dvořáková A, Holubec L jr. et al. Farmakoekonomika cytostatické a biologické léčby pokročilého kolorektálního karcinomu. XVIII. Jihočeské onkologické dny 2011. A14.

3. Jirásková L, Doležal T. Farmakoekonomická analýza capecitabinu v adjuvantní léčbě kolorektálního karcinomu – srovnání s režimem 5-FU/LV. Farmakoekonomika 2006; 2: 56–63.

4. Doležal T. Analýza nákladové efektivity capecitabinu v adjuvantní terapii karcinomu tlustého střeva v podmínkách České republiky. Farmakoekonomika 2011; 5 (1): 3–5.

5. Twelves C, Wong A, Nowacki MP et al. Capecitabine as Adjuvant Treatment for Stage III Colon Cancer (X-ACT Trial). N Engl J Med 2005; 352 (26): 2696–2704.

6. Aitini E, Rossi A, Morselli P et al. Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer. Cancer Manag Res 2012; 4: 99–103.

7. Tse VC, Ng WT, Lee V et al. Cost-analysis of XELOX and FOLFOX-4 for treatment of colorectal cancer to assist decision-making on reimbursement. BMC Cancer 2011; 11: 288.

8. Maniadakis N, Fragoulakis V, Pectasides D et al. XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis. Curr Med Res Opin 2009; 25(3): 797–805.

9. Perrocheau G, Bennouna J, Ducreux M et al. Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6. Oncology 2010; 79 (3–4): 174–180.

10. Cassidy J, Schmoll HJ, Van Cutsem E. Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer? J Clin Oncol 2008; 26(13): 2226–2227.

11. Douillard JY, Bennouna J, Senellart H. Is XELOX equivalent to FOLFOX or other continuous-infusion 5-fluorouracil chemotherapy in metastatic colorectal cancer? Clin Colorectal Cancer 2008; 7(3): 206–211.

12. Moosmann N, von Weikersthal LF, Vehling-Kaiser U et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104 – a randomized trial of the German AIO CRC study group. J Clin Oncol 2011; 29(8): 1050–1058.

13. Maughan TS, Adams RA, Smith CG et al. MRC COIN Trial Investigators. Addition of cetuximab to oxaliplatin-based fi rst-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377 (9783): 2103–2114.

14. Cassidy J, Clarke S, Díaz-Rubio E et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26(12): 2006–2012.